CERENOME, INC.
CNSY · XNASCIK 1095981fmd_0WE0GR85CKC9Z27AFCT5X5KRP9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 3 | 1 | – | – | – | – | 5 | 6 | 5 |
| Cost of revenue | 3 | 1 | 1 | – | – | – | – | – | – | – |
| Gross profit | 2 | 0 | (0) | – | – | – | – | – | – | – |
| Research and development | 16 | 5 | 6 | 5 | 3 | 5 | 10 | 10 | 11 | 8 |
| Selling, general and administrative | 12 | 8 | 6 | 5 | – | – | – | – | – | – |
| Total operating expenses | 28 | 15 | 12 | 11 | 10 | 12 | 20 | 18 | 21 | 21 |
| Operating income | (20) | (11) | (9) | (4) | (10) | (12) | (20) | (13) | (15) | (15) |
| Interest expense | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 1 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (2) | (2) | (0) | 0 | 1 | (1) | (1) | 0 | 2 | (7) |
| Income before taxes | (22) | (13) | (9) | (3) | – | – | – | – | (13) | (22) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (22) | (13) | (9) | (3) | (8) | – | – | – | (13) | (22) |
| Net income | (22) | (23) | (13) | (11) | (8) | (13) | (20) | (13) | (13) | (22) |
| Net income to common shareholders | (22) | (27) | (15) | (11) | (8) | – | – | (13) | (18) | (22) |